Apellis Pharmaceuticals Inc
APLS
Market Cap$3.48B
Close$
$-40.45
241.2% downside
Current Fair Value
241.2% downsideOvervalued by 241.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.48 Billion |
|---|---|
| Enterprise Value | $3.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.6 |
| Beta | 0.77 |
| Outstanding Shares | 126,024,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.23 |
|---|---|
| PEG | -127.6 |
| Price to Sales | 5.73 |
| Price to Book Ratio | 28.65 |
| Enterprise Value to Revenue | 4.5 |
| Enterprise Value to EBIT | -15.32 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Apellis Pharmaceuticals Inc
CEO: Cedric Francois